文献速递结核与非结核分枝杆菌

大观酰胺作为结核治疗伙伴药物在多种小鼠感染模型中有效

Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

该研究在小鼠结核模型中评估先导大观酰胺1599或1810单用及与现有或新型抗结核药联用的体内活性。结果显示1599与多数一线药物呈相加或协同作用,与利福平+吡嗪酰胺或贝达喹啉+吡嗪酰胺联用显著提高疗效,且在慢性感染和干酪样坏死模型中亦增强疗效。

要点

  • 大观酰胺1599与多数一线抗结核药呈相加或协同活性。
  • 1599联合利福平+吡嗪酰胺或贝达喹啉+吡嗪酰胺显著提高小鼠模型疗效。
  • 体外MIC棋盘试验未能预测上述体内协同作用。

核心结论

  • 大观酰胺是贝达喹啉、利福平和吡嗪酰胺等多种抗结核药物的有效伙伴药物。

研究设计与样本

  • 在三种逐步进展的结核小鼠模型中,经气溶胶感染建立急性或慢性感染后,治疗≤4周,单用大观酰胺或与现有及新型抗结核药组成两药和三药方案,肺匀浆铺板计数cfu。

主要发现

  • 1599与多数一线药物呈相加或协同活性。
  • 1599联合利福平+吡嗪酰胺或贝达喹啉+吡嗪酰胺在高剂量气溶胶模型中显著提高疗效。
  • 1599增强利福平或吡嗪酰胺在慢性感染BALB/c小鼠中的疗效。
  • 在显示干酪样坏死性肺部病变的C3HeB/FeJ小鼠模型中,1599联合利福平+吡嗪酰胺呈协同作用。

临床怎么用

  • 支持进一步开发大观酰胺作为现有和实验性抗结核药的联合伙伴。

局限性

  • 体外MIC棋盘试验未能预测体内协同相互作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: New drug regimens employing combinations of existing and experimental antimicrobial agents are needed to shorten treatment of tuberculosis (TB) in humans. The spectinamides are narrow-spectrum semisynthetic analogues of spectinomycin, modified to avoid intrinsic efflux by Mycobacterium tuberculosis . Spectinamides, including lead 1599, have been previously shown to exhibit a promising therapeutic profile in mice as single agents. Here we explore the in vivo activity of lead spectinamides when combined with other agents. METHODS: The efficacy of 1599 or 1810 was tested in combination in three increasingly advanced TB mouse models. Mice were infected by aerosol and allowed to establish acute or chronic infection, followed by treatment (≤4 weeks) with the spectinamides alone or in two- and three-drug combination regimens with existing and novel therapeutic agents. Bacteria were enumerated from lungs by plating for cfu. RESULTS: Herein we show the following: (i) 1599 exhibits additive or synergistic activity with most of the first-line agents; (ii) 1599 in combination with rifampicin and pyrazinamide or with bedaquiline and pyrazinamide promotes significantly improved efficacy in the high-dose aerosol model; (iii) 1599 enhances efficacy of rifampicin or pyrazinamide in chronically infected BALB/c mice; and (iv) 1599 is synergistic when administered in combination with rifampicin and pyrazinamide in the C3HeB/FeJ mouse model showing caseous necrotic pulmonary lesions. CONCLUSIONS: Spectinamides were effective partner agents for multiple anti-TB agents including bedaquiline, rifampicin and pyrazinamide. None of these in vivo synergistic interactions was predicted from in vitro MIC chequerboard assays. These data support further development of the spectinamides as combination partners with existing and experimental anti-TB agents.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Robertson GT, Scherman MS, Bruhn DF, et al. Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models. J Antimicrob Chemother. 2017. PMID: 27999020. doi:10.1093/jac/dkw467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。